19 June 2013
Keywords: UCB, Domainex, CDH technology, Cancer drug targets
Article | 12 March 2012
Belgian drugmaker UCB (Euronext Brussels: UCB) and Domainex, a UK-based drug discovery company, have jointly published the results of a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
12 March 2012
18 June 2013
© 2013 thepharmaletter.com